Meeting
2018 ASCO Annual Meeting
Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.
Authors
Benjamin Philip Levy
Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Sibley Memorial Hospital, Washington DC, MD
Benjamin Philip Levy , Luis G. Paz-Ares , Jaafar Bennouna , Enriqueta Felip , Delvys Rodríguez Abreu , Dolores Isla , Fabrice Barlesi , Olivier Molinier , Jeannick Madelaine , Clarisse Audigier-Valette , Sang-We Kim , Mustafa Ozguroglu , Mustafa Erman , Firas Benyamine Badin , Tarek Mekhail , Ronald J. Scheff , Jonathan W. Riess
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03157089
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9117)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9117
Abstract #
TPS9117
Poster Bd #
433b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
First Author: Minal A. Barve
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2020 ASCO Virtual Scientific Program
Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) as monotherapy or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N.
First Author: Tony S. K. Mok
Poster
2019 ASCO Annual Meeting
EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.
First Author: Martin David Forster